Glucocorticoid-induced osteoporosis

Stuart L. Silverman, Nancy E Lane

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Glucocorticoid treatment can alter bone metabolism, reduce bone strength, and increase the risk for osteoporotic fractures. Risk factors for glucocorticoid-induced osteoporosis (GIO) include older age, high doses, and longer duration of glucocorticoid use. The bone loss that accompanies glucocorticoid use is rapid, and early treatment with bone-sparing agents can prevent bone loss and reduce fracture risk. Several randomized controlled clinical trials have found prevention and treatment of GIO with bisphosphonates, and recently the treatment of GIO with teriparatide, to be effective. This article reviews current information on the epidemiology, pathophysiology, and clinical studies that support using bone-active agents to prevent and treat GIO.

Original languageEnglish (US)
Pages (from-to)23-26
Number of pages4
JournalCurrent Osteoporosis Reports
Volume7
Issue number1
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Glucocorticoids
Osteoporosis
Bone and Bones
Teriparatide
Osteoporotic Fractures
Diphosphonates
Epidemiology
Randomized Controlled Trials

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Glucocorticoid-induced osteoporosis. / Silverman, Stuart L.; Lane, Nancy E.

In: Current Osteoporosis Reports, Vol. 7, No. 1, 2009, p. 23-26.

Research output: Contribution to journalArticle

Silverman, Stuart L. ; Lane, Nancy E. / Glucocorticoid-induced osteoporosis. In: Current Osteoporosis Reports. 2009 ; Vol. 7, No. 1. pp. 23-26.
@article{ff04a9e391c44676865c3b687777a5b2,
title = "Glucocorticoid-induced osteoporosis",
abstract = "Glucocorticoid treatment can alter bone metabolism, reduce bone strength, and increase the risk for osteoporotic fractures. Risk factors for glucocorticoid-induced osteoporosis (GIO) include older age, high doses, and longer duration of glucocorticoid use. The bone loss that accompanies glucocorticoid use is rapid, and early treatment with bone-sparing agents can prevent bone loss and reduce fracture risk. Several randomized controlled clinical trials have found prevention and treatment of GIO with bisphosphonates, and recently the treatment of GIO with teriparatide, to be effective. This article reviews current information on the epidemiology, pathophysiology, and clinical studies that support using bone-active agents to prevent and treat GIO.",
author = "Silverman, {Stuart L.} and Lane, {Nancy E}",
year = "2009",
doi = "10.1007/s11914-009-0005-4",
language = "English (US)",
volume = "7",
pages = "23--26",
journal = "Foodborne Pathogens and Disease",
issn = "1744-165X",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Glucocorticoid-induced osteoporosis

AU - Silverman, Stuart L.

AU - Lane, Nancy E

PY - 2009

Y1 - 2009

N2 - Glucocorticoid treatment can alter bone metabolism, reduce bone strength, and increase the risk for osteoporotic fractures. Risk factors for glucocorticoid-induced osteoporosis (GIO) include older age, high doses, and longer duration of glucocorticoid use. The bone loss that accompanies glucocorticoid use is rapid, and early treatment with bone-sparing agents can prevent bone loss and reduce fracture risk. Several randomized controlled clinical trials have found prevention and treatment of GIO with bisphosphonates, and recently the treatment of GIO with teriparatide, to be effective. This article reviews current information on the epidemiology, pathophysiology, and clinical studies that support using bone-active agents to prevent and treat GIO.

AB - Glucocorticoid treatment can alter bone metabolism, reduce bone strength, and increase the risk for osteoporotic fractures. Risk factors for glucocorticoid-induced osteoporosis (GIO) include older age, high doses, and longer duration of glucocorticoid use. The bone loss that accompanies glucocorticoid use is rapid, and early treatment with bone-sparing agents can prevent bone loss and reduce fracture risk. Several randomized controlled clinical trials have found prevention and treatment of GIO with bisphosphonates, and recently the treatment of GIO with teriparatide, to be effective. This article reviews current information on the epidemiology, pathophysiology, and clinical studies that support using bone-active agents to prevent and treat GIO.

UR - http://www.scopus.com/inward/record.url?scp=65449128895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65449128895&partnerID=8YFLogxK

U2 - 10.1007/s11914-009-0005-4

DO - 10.1007/s11914-009-0005-4

M3 - Article

C2 - 19239826

AN - SCOPUS:65449128895

VL - 7

SP - 23

EP - 26

JO - Foodborne Pathogens and Disease

JF - Foodborne Pathogens and Disease

SN - 1744-165X

IS - 1

ER -